Videos

The director of the Comprehensive Epilepsy Center at NYU Langone provided closing thoughts on how clinicians can begin to shift gears from research to prevention of SUDEP. [WATCH TIME: 2 minutes]

Discussing newer treatment options in the MS field, the staff neurologist in the Neurological Institute’s Mellen Center for Multiple Sclerosis Treatment and Research at Cleveland Clinic noted that patient preference can play a part in the decision-making process. [WATCH TIME: 3 minutes]

The director of the Sleep-Wake Disorders Center at Montefiore Medical Center provided knowledge on how the presence of other comorbid sleep disorders affects patients with insomnia. [WATCH TIME: 2 minutes]

The staff neurologist in the Neurological Institute’s Mellen Center for Multiple Sclerosis Treatment and Research at Cleveland Clinic discussed emerging treatments in the MS field. [WATCH TIME: 2 minutes]

A migraine specialist examines the efficacy and safety of oral CGRP antagonist ubrogepant for the acute treatment of migraine.

Dr David Kudrow discusses how CGRP antagonist treatments have affected chronic migraine, including the effect on quality of life.

The director of the Comprehensive Epilepsy Center at NYU Langone discussed the necessary steps in validating and utilizing heart rate variability as a biomarker for SUDEP. [WATCH TIME: 3 minutes]

The rationale for early treatment initiation for patients with relapsing-remitting multiple sclerosis.

Expert neurologists provide insight on how to decide on an on-demand therapy for Parkinson’s disease and provide some general advice.

The patient symptoms that help neurologists distinguish relapsing and remitting multiple sclerosis from other forms of the disease, and recommendations regarding the best timing to initiate therapy.

Key opinion leaders explain the use of sublingual apomorphine and trimethobenzamide for Parkinson’s disease.

The director of the Mellen Center for MS Treatment and Research at Cleveland Clinic discussed when clinicians should anticipate new therapies to treat progressive MS. [WATCH TIME: 2 minutes]

The executive chair of the Rockefeller Neuroscience Institute at West Virginia University discussed the potential of focused ultrasound for patients with AD, as well as key takeaways for clinicians from a recent study. [WATCH TIME: 5 minutes]

Episode 16 of the AUPN Leadership Minute features Rohit Das, MD, of UT Southwestern Medical Center; and Selim R. Benbadis, MD, FAAN, FACNS, FAES, University of South Florida Morsani College of Medicine. [WATCH TIME: 4 minutes]

Neurology News Network for the week ending November 20, 2021.

The executive chair of the Rockefeller Neuroscience Institute at West Virginia University spoke on how technology can be used to open the blood-brain barrier in patients with AD. [WATCH TIME: 7 minutes]

Elizabeth Thiele, MD, PhD, and Elaine C. Wirrell, MD, discuss the FDA approval of cannabidiol as an oral solution for the treatment of seizures, specifically for both Dravet and Lennox-Gastaut syndromes.

Two experts detail the current treatment options for Dravet and Lennox-Gastaut syndromes and how they select which patients should use a specific drug.

Expert neurologists share their goals and patient considerations for preventive migraine therapy.

Andrew C. Charles, MD, provides a historical perspective on the agents traditionally used for preventive migraine therapy.

Expert neurologist and sleep specialist Chris Winter, MD, discusses the FDA approval of pitolisant for patients with narcolepsy and excessive daytime sleepiness in the context of his own experience with this novel agent.

Expert insight on the mechanism of action and use of subcutaneous apomorphine hydrochloride in patients with Parkinson disease.

Insight on the proper evaluation of excessive daytime sleepiness in patients with narcolepsy, as well as agents that have been used to manage this condition.

Peter A. LeWitt, MD, considers the mechanism of action and use of levodopa inhalation powder in patients with Parkinson disease.

The director of the Comprehensive Epilepsy Center at NYU Langone provided insight on whether a newly discovered biomarker can play a role in the creation of modalities to detect SUDEP risk. [WATCH TIME: 3 minutes]

Chaired by Jennifer Graves, MD, PhD, MAS, the presentations also feature UC San Diego Health experts Jenelle Raynowska, MD; Jennifer Yang, MD; and Anastasie Dunn-Pirio, MD. [WATCH TIME: 1 hour, 23 minutes]

The postdoctoral scholar at the University of Iowa commented on why the multiple sclerosis field should lean on registered dietitians to help alleviate symptoms of patients with multiple sclerosis. [WATCH TIME: 2 minutes]

Discussing cognitive behavioral therapy for patients with MS, the associate professor of Physical Medicine and Rehabilitation and research nonclinical psychologist at the University of Michigan Medicine mentioned different therapeutic options that can benefit this patient population. [WATCH TIME: 3 minutes]

An expert neurologist explains how to decide on migraine treatment with a patient and when to consider preventive treatment.

David Kudrow, MD, defines episodic and chronic migraine and details how symptoms differ.